South China Morning Post | January 1, 2022
Lawrence Gostin, faculty director of the O’Neill Institute for National and Global Health Law at Georgetown University in the US, said it was possible some doses – including those relied on by Covax – may not hold up well against Omicron, potentially putting more demand on production of those that do.